Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

Inclusion Criteria: * HIV infected * Currently on ART consisting of at least 3 antiretroviral drugs for at least 12 months prior to study entry and stable (no change in dose) on treatment for at least 3 months prior to study entry * CD4 count of 100 cells/mm3 or more within 42 days of study entry * Viral load of 50,000 copies/ml or less within 42 days of study entry * Willing to use acceptable forms of contraception * Participants with a Category C AIDS-defining illness during the 12 months prior to study entry may be eligible as long as their CD4 count is 200 cells/mm3 or more at screening. Participants with Kaposi's sarcoma may also be eligible for this study. Exclusion Criteria: * Lymphadenopathy greater than 2.0 cm * Known allergy or sensitivity to study drug or its formulations * Current drug or alcohol abuse * Serious illness or hospitalization that, in the opinion of the site investigator, may interfere with the study results * Prior use of any interleukins * Systemic cancer chemotherapy, systemic investigational agents, or immunomodulators (e.g., growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interferons) within 90 days prior to study entry * Heparin within 96 hours prior to study entry, or anticipating the need for heparin within 96 hours after the study injection * History of cancer (except basal carcinoma of the skin or Kaposi's sarcoma) * Enlargement of spleen * History of hypercoagulability (deep vein thrombosis or pulmonary embolism) * History of seizure disorder * History of extensive psoriasis, Crohn's disease, uveitis, or other autoimmune disease having induced severe complications * Significant psychiatric, cardiac, pulmonary, thyroid, renal, or neurological disease requiring therapy * Positive hepatitis B surface antigen or positive hepatitis C antibody at screening * Plan to start new ART within 8 weeks after study entry * Breastfeeding